RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @leidl_r: Indeed this systematic review underlines that #QualityofLife should receive a greater role in trials. Other research points ou…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
Indeed this systematic review underlines that #QualityofLife should receive a greater role in trials. Other research points out that patient-reported outcomes (#PROs) also require further development as indications in the drug label https://t.co/0HJBe8599p
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
RT @DorteGyrd: New publication poses the question: Is progression-free survival associated with health-related quality of life in studies o…
New publication poses the question: Is progression-free survival associated with health-related quality of life in studies of cancer treatments? The answer is “no” - so let us please generate HRQoL of life data, and not use PFS as a proxy! https://t.co/nP
Para garantizar un beneficio importante de las terapias contra el cáncer, los investigadores de los ensayos clínicos deben medir la CVRS de manera directa y precisa, asegurando una duración y un seguimiento adecuados. https://t.co/ksKEBot4Pg
RT @Bealoquebea: progression-free survival associated with health-related quality of life or not? https://t.co/MkNgW9rLIo
progression-free survival associated with health-related quality of life or not? https://t.co/MkNgW9rLIo
Revision sistemática Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/kAO6mWSXIn
Revue systématique ne trouvant pas d’association entre l’augmentation de la durée de survie sans progression reliée à la chimiothérapie et la qualité de vie des patients https://t.co/BBH38wubYj https://t.co/CoHejoGc36
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @EBCPMcMaster: Should we care about progression-free cancer survival? Does improved PFS indicate improved quality of life. A new syste…
Fantastic. Need to strive to move away from PFS as an endpoint in oncology drug trials.
RT @EBCPMcMaster: Should we care about progression-free cancer survival? Does improved PFS indicate improved quality of life. A new syste…
Should we care about progression-free cancer survival? Does improved PFS indicate improved quality of life. A new systematic review suggests not. https://t.co/RGos8XyXuj https://t.co/7QYjymVgCf
@MammaMiaMagazin @oncology_bg Just ran across this, in which I thought you might be interested. https://t.co/7vtk76Sy35
RT @colbertle: We love PFS in oncology- not saying it shouldn’t be used or approved, but pts should know when a tx is approved/ offered tha…
RT @colbertle: We love PFS in oncology- not saying it shouldn’t be used or approved, but pts should know when a tx is approved/ offered tha…
RT @colbertle: We love PFS in oncology- not saying it shouldn’t be used or approved, but pts should know when a tx is approved/ offered tha…
Happy New Year @FDAOncology @EMA_News @DKMA_dk @LifDK @DagensMedicinDK
Thoughts @drdavidpalma ?
RT @colbertle: We love PFS in oncology- not saying it shouldn’t be used or approved, but pts should know when a tx is approved/ offered tha…
We love PFS in oncology- not saying it shouldn’t be used or approved, but pts should know when a tx is approved/ offered that it may not improve OS or QoL and be allowed to say No Thanks. #shareddecisionmaking
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/YY0eIi5ABa
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @PeterBOstergren: Better incorporation of patient symptom control and QoL primary endpoints are warranted in future oncology trials http…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @Abdallah81MD: Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic…
Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis | Oncology | JAMA Internal Medicine | JAMA Network @JAMA_current @JAMAOnc https://t.co/Z2EcYSuiNK
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @docdu16: A lire, faire lire, faire relire. https://t.co/9l5JaY0W5n
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
A lire, faire lire, faire relire.
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
Progression-Free Survival challenged as a Surrogate Outcome for Health-Related Quality of Life in #cancer https://t.co/TxAyUCSDuT
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @kevin_radonc: “These findings raise questions about the assumption that interventions prolonging PFS also improve HRQoL in patients wit…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @kevin_radonc: “These findings raise questions about the assumption that interventions prolonging PFS also improve HRQoL in patients wit…
RT @kevin_radonc: “These findings raise questions about the assumption that interventions prolonging PFS also improve HRQoL in patients wit…
RT @rocatanho: We failed to find assoc between progression-free survival (PFS) & HRQoL in cancer clinical trials. Clinical trial investiga…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
RT @PeterBOstergren: Better incorporation of patient symptom control and QoL primary endpoints are warranted in future oncology trials http…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @GENESIS_SEFH: #RevisiónSistemática Evaluación de la SLP como variable subrogada de la calidad de vida en oncología: sin asociación sign…
RT @JAMAInternalMed: This systematic review and analysis finds that for oncology patients, improvement in #PFS does not correlate with impr…
Better incorporation of patient symptom control and QoL primary endpoints are warranted in future oncology trials
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @EmilioAlegre1: Comprobado: por aumentar SLP no mejora la calidad de vida. Así que, cuando la variable SG se mantiene sin mejorar, el au…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
RT @_sarahweller: If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https:…
If you missed this one when it first hit the web, it is WORTH the read. A very important #oncology paper for 2018. https://t.co/qzHPOp9lZ5 Very interested in your thoughts & main takeaways... #ExerciseOncology